Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved its drug to treat rare and potentially fatal disorders involving loss of body fat. The condition, known as generalized lipodystrophy, involves fat buildup in the blood and organs such as liver and muscle and can lead to diabetes, pancreatitis and fatty liver disease.
Help employers find you! Check out all the jobs and post your resume.
